Kamada (KMDA) Receivables - Net (2012 - 2026)
Kamada's (KMDA) quarterly Receivables - Net came in at $36.7 million in Q2 2026, up 20.35% on a YoY basis from $30.5 million in Q2 2025, and up 0.53% quarter-over-quarter from $36.5 million in Q1 2026.
Analysis
Kamada (KMDA) Receivables - Net (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Receivables - Net for 15 consecutive years, with $36.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Receivables - Net rose 20.35% year-over-year to $36.7 million; the trailing twelve-month figure through Jun 2026 stood at $36.7 million (up 20.35% YoY), and the FY2025 full-year result was $27.0 million, up 25.34% from the prior year.
- Receivables - Net improved to $36.7 million in Q2 2026 per KMDA's latest filing, from $36.5 million in the prior quarter.
- Across five years, Receivables - Net topped out at $36.7 million in Q2 2026 and bottomed at $16.3 million in Q3 2024.
- Historically, Receivables - Net has averaged $25.2 million across 5 years, with a median of $24.8 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Receivables - Net tumbled 36.06% in 2022, then soared 92.57% in 2025.
- Over 5 years, Receivables - Net stood at $27.3 million in 2022, then slipped by 27.06% to $19.9 million in 2023, then grew by 8.4% to $21.5 million in 2024, then climbed by 25.34% to $27.0 million in 2025, then surged by 35.92% to $36.7 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $36.7 million, $36.5 million, and $27.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.39 Bn | 197.40 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.14 Bn | 177.96 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.91 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.55 Bn | 56.36 Bn | 1.37 Bn |
| 6 | Moderna | 54.39 Bn | 49.25 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.43 Bn | 31.12 Bn | 992.69 Mn |
| 8 | Biogen | 31.18 Bn | 29.89 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn |
| 10 | Kamada | 472.70 Mn | 402.57 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.71 Mn |
| Mar 31, 2026 | 36.52 Mn |
| Dec 31, 2025 | 27.01 Mn |
| Sep 30, 2025 | 31.38 Mn |
| Jun 30, 2025 | 30.50 Mn |
| Mar 31, 2025 | 27.88 Mn |
| Dec 31, 2024 | 21.55 Mn |
| Sep 30, 2024 | 16.30 Mn |
| Jun 30, 2024 | 26.23 Mn |
| Mar 31, 2024 | 18.86 Mn |
| Dec 31, 2023 | 19.88 Mn |
| Sep 30, 2023 | 25.11 Mn |
| Jun 30, 2023 | 24.58 Mn |
| Mar 31, 2023 | 20.93 Mn |
| Dec 31, 2022 | 27.25 Mn |
| Sep 30, 2022 | 24.00 Mn |
| Jun 30, 2022 | 17.74 Mn |
| Mar 31, 2022 | 21.57 Mn |
| Dec 31, 2021 | 35.16 Mn |
| Sep 30, 2021 | 26.55 Mn |